JAMA ophthalmology
-
Randomized Controlled Trial Multicenter Study
Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials.
The impact of vitreomacular adhesion (VMA) resolution on patient-reported visual function in symptomatic VMA/vitreomacular traction (VMT) has not yet been documented, to our knowledge. ⋯ Ocriplasmin produces clinically meaningful improvement in patient-reported visual function in symptomatic VMA/VMT.